Home
Site Map
Contact Us
Graphics Version
Printer Version
Main Navigation
ABOUT US
COMPANY PROFILE
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGY
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
EXECUTIVE MANAGEMENT TEAM
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
BOARD OF DIRECTORS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
CONTACT US
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
THERAPEUTIC FOCUS
CARDIOVASCULAR
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
PRODUCTS
PIPELINE
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for Reducing Cardiovascular Risk
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
SCIENCE & TECHNOLOGY
INTRODUCTION
Lipophilic Platform
Targeted Lipid Transport Technology Platform
Cholinergic Platform
PARTNERING
PARTNERING
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
STOCK INFORMATION
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
CORPORATE GOVERNANCE
AUDIT COMMITTEE
REMUNERATION COMMITTEE
CODE OF ETHICS
MEMORANDUM AND ARTICLES OF ASSOCIATION
PRESENTATIONS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
PRESS RELEASES
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR FAQ
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INVESTOR KIT
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
FINANCIAL REPORTS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
SEC FILINGS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
EGM 2008
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
ANALYST COVERAGE
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
EMAIL ALERTS
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INFORMATION
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
STOCK INFORMATION
CORPORATE GOVERNANCE
PRESENTATIONS
PRESS RELEASES
Recent
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
INVESTOR FAQ
REQUEST INVESTOR KIT
FINANCIAL REPORTS
SEC FILINGS
EGM 2008
ANALYST COVERAGE
EMAIL ALERTS
REQUEST INFORMATION
Mailing List
Join our mailing list if you wish to receive updates by email
Mailing List
Unsubscribe »
INVESTOR
RELATIONS
PRESS RELEASES
3-Mar-2010
Amarin to Present at the Cowen and Company Healthcare Conference
11-Feb-2010
AMARIN APPOINTS JAN VAN HEEK NON-EXECUTIVE DIRECTOR
2-Feb-2010
Amarin To Present at the 12th Annual BIO CEO & Investor Conference
28-Jan-2010
AMARIN PROVIDES 2009 YEAR-END REVIEW TO SHAREHOLDERS
11-Jan-2010
AMARIN CORPORATION ANNOUNCES FIRST PATIENTS ENROLLED IN TWO PHASE 3 CLINICAL TRIALS ASSESSING AMR101 FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
Web Design by Webtrade.ie